The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.
 
Georgina Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; GI Innovation Inc; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron; Scancell LImited; Skyline Diagnostics
 
Paolo Ascierto
Consulting or Advisory Role - Anaveon; Bayer; Bio-AI Health; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Erasca, Inc; Genmab; Immunocore; Italfarmaco; Lunaphore Technologies; Medicenna; Menarini Silicon Biosystems; Merck Sharp & Dohme; Nouscom; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Sun Pharma; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Philogen; Pierre Fabre; Replimune
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere
 
Sunandana Chandra
Honoraria - Bristol Myers Squibb; Immunocore; Merck; Novartis; Pfizer; Regeneron; Replimune; Sanofi/Regeneron
Consulting or Advisory Role - Alkermes; Array BioPharma; Bristol-Myers Squibb; Celltrion; EMD Serono; Exicure; Novartis; Pfizer; Sanofi/Regeneron
Research Funding - Bristol Myers Squibb Foundation (Inst); exicure (Inst); Immunocore (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Replimune (Inst); Sanofi/Regeneron (Inst); Werewolf Therapeutics (Inst)
 
Ahmad Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Nested; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst)
 
Eva Muñoz Couselo
Honoraria - BMS; Immunocore; MSD; Novartis; Pierre Fabre; Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Immunocore; Menarini; MSD; Novartis; Pierre Fabre; Regeneron; Sanofi
Speakers' Bureau - Bristol-Myers Squibb/Celgene; MSD; Novartis; Pierre Fabre; Sanofi
 
Michele Del Vecchio
Consulting or Advisory Role - Bristol Myers Squibb; Immunocore; Merck; Novartis; Pierre Fabre
 
Andreia Melo
Honoraria - AstraZeneca; BMS; GlaxoSmithKline; MSD Oncology; Novartis; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD; Novartis
Research Funding - AstraZeneca (Inst); BMS Brazil (Inst); Clovis Oncology (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; Genesis Pharmaceuticals; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Replimune (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD; Pfizer; Sanofi
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Oncobit; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Simcere; Sun Pharma; T3 Pharmaceuticals; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Oncobit; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Simcere; Sun Pharma; T3 Pharmaceuticals; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Margaret Callahan
Employment - Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Celgene (I); Kleo Pharmaceuticals (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Epitopea; Immunocore; Merck; Moderna Therapeutics
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Clinical Care Options; Potomac Center for Medical Education
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Agenus (Inst); Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Peter Koelblinger
Honoraria - BMS; MSD Oncology; Pierre Fabre; Sanofi
Consulting or Advisory Role - BMS; MSD Oncology
Research Funding - BMS
Expert Testimony - MSD Oncology
Travel, Accommodations, Expenses - Pierre Fabre
 
Gaelle Quereux
No Relationships to Disclose
 
Ioannis Thomas
Research Funding - 4SC (Inst); 4SC (Inst); Amgen (Inst); argenx (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Biotech Pharmacal (Inst); BMS (Inst); cerpass (Inst); CureVac (Inst); Genentech (Inst); HUYA Bioscience International (Inst); idera (Inst); Incyte (Inst); InflaRx (Inst); Iovance Biotherapeutics (Inst); Kartos Therapeutics (Inst); LEO Pharma (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); UCB (Inst)
 
Bohang Chen
No Relationships to Disclose
 
Alicia Cheong
Patents, Royalties, Other Intellectual Property - Bristol-Myers Squibb (Inst)
 
Patrick Djidel
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
Travel, Accommodations, Expenses - Bristol Myers Squibb
 
Sonia Dolfi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Hussein Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Genentech/Roche; IO Biotech; Iovance Biotherapeutics; Jazz Pharmaceuticals; Medicenna; Merck; Novartis; Pfizer; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst)